Search results for "antineoplastic"

showing 10 items of 2217 documents

Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…

2021

Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…

Molecular dynamicAntineoplastic Agents Hormonalmedicine.drug_classIn silicoEstrogen receptorBreast NeoplasmsMolecular dynamicsQM/MMBreast cancerbreast cancerDrug DiscoverymedicineHumansAromataseIC50Pharmacologychemistry.chemical_classificationbiologyAromatase InhibitorsMultitargetOrganic ChemistryEstrogen AntagonistsAromatase inhibitorGeneral Medicinemedicine.diseaseSERMEnzymechemistryEstrogenCell cultureSettore CHIM/03 - Chimica Generale E InorganicaSERDbiology.proteinCancer researchFemale
researchProduct

Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.

2019

Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers (BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) is currently one of the most effective therapies against ER + BC. Yet, the development of acquired resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous findings indicate that aromatase may be non-competitively inhibited by clinically employed drugs and/or industrial chemicals. Here, by performing in silico screening on two putative allosteric sites, molecular dynamics and free energy simulations, supported by enzymatic and cell-based assays, we id…

Molecular dynamicmedicine.drug_classIn silicoAllosteric regulationCytochromes P450; Aromatase; Molecular dynamics; Aromatase inhibitors; Docking; Breast cancer; Resistance onset; Mixed inhibition mechanismAntineoplastic AgentsBreast NeoplasmsMolecular dynamicsMolecular Dynamics SimulationDockingStructure-Activity RelationshipBreast cancerBreast cancerAromataseAllosteric RegulationCell Line TumorDrug DiscoverymedicineResistance onsetHumansMixed inhibition mechanismAromataseEnzyme InhibitorsCell ProliferationPharmacologychemistry.chemical_classificationbiologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryRational designAromatase inhibitorGeneral Medicinemedicine.diseaseEnzymeAromatase inhibitorsSettore CHIM/03 - Chimica Generale E InorganicaEstrogenDocking (molecular)Drug Designbiology.proteinCancer researchDrug Screening Assays AntitumorCytochromes P450European journal of medicinal chemistry
researchProduct

Design, synthesis and biological evaluation of novel stilbene-based antitumor agents

2008

A series of novel stilbene derivatives has been synthesized and studied with the main goal to investigate SAR of the amino compound 1a, as well as to improve its water solubility, a potentially negative aspect of the molecule that could be a serious obstacle for a pre-clinical development. We have obtained derivatives with good cytotoxic activity, in particular, the derivatives 5c and 6b could represent two novel leads for further investigation. Compound 8b, a morpholino-carbamate derivative, prodrug of 1a, has a very good solubility in water, and is active in suppressing growth of tumor cells at a concentration of 5000 nM, which is a concentration 100 times higher than the parent stilbene …

Molecular modelClinical BiochemistryAntitumor agents; Prodrugs; Stilbenes;Pharmaceutical ScienceAntineoplastic AgentsBiochemistryChemical synthesisStructure-Activity RelationshipTubulinCell Line TumorStilbenesDrug DiscoveryHumansMoleculeOrganic chemistryProdrugsAminesSolubilityMolecular BiologyCell Proliferationchemistry.chemical_classificationAqueous solutionDose-Response Relationship DrugOrganic ChemistryAromatic amineProdrugCombinatorial chemistryIn vitroSolubilitychemistryDrug DesignMolecular MedicineBioorganic & Medicinal Chemistry
researchProduct

Ramucirumab and its use in gastric cancer treatment

2014

Abstract: The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several sol…

Monoclonal antibodyGene isoformmedicine.drug_classAngiogenesisAngiogenesis; Gastroesophageal junction cancer; Metastatic gastric cancer; Monoclonal antibody; Ramucirumab; VEGF receptors; Pharmacology; Pharmacology (medical)Antineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroesophageal junction cancerMonoclonal antibodyRamucirumabRamucirumabchemistry.chemical_compoundStomach NeoplasmsmedicineHumansPharmacology (medical)ReceptorVEGF receptorsPharmacologyClinical Trials as Topicbusiness.industryPharmacology. TherapyVEGF receptorAntibodies MonoclonalLigand (biochemistry)Vascular Endothelial Growth Factor Receptor-2BlockadeVascular endothelial growth factorAngiogenesichemistryAngiogenesisbusinessMetastatic gastric cancerDrugs of Today
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

Adverse Reactions to Anticancer Drugs in the Oral Cavity

2018

The development, testing, and adoption into clinical practice of anticancer medications have revolutionized cancer care over the past decades. A better understanding of the biology of cancer has translated into development of novel systemic agents, as well a more effective use of older chemotherapy agents. As a consequence, cancer mortality continues to decrease. However, greater cure and disease control rates come at a price of an increased risk of adverse effects, which often affects the mouth and related structures including the oral mucosa, salivary glands, jawbones, and cranial nerves. Oral mucositis, hyposalivation, dysgeusia, and osteonecrosis of the jaw (ONJ) are some examples of th…

MouthArticle SubjectGeneral Immunology and Microbiologybusiness.industrylcsh:RMEDLINElcsh:MedicineAntineoplastic AgentsGeneral MedicineOral cavityBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyEditorialText miningHumansMedicineMouth DiseasesbusinessBioMed Research International
researchProduct

Effect of zinc on oropharyngeal mucositis in children with acute leukemia undergoing chemotherapy

2020

Background Oropharyngeal mucositis (OM) is one of the main side-effects of oncological therapy. There is no treatment to prevent its occurrence, but some zinc-based therapies have been proven to help in decreasing its intensity. The objective of this study was to determine the effect of zinc in OM in children with acute leukemia in the early stages of oncological treatment. Material and Methods This quasi-experimental study evaluated OM in 2 groups (control group: conventional hospital management, and experimental group: administration of 50 mg of zinc gluconate daily plus conventional hospital management). OM severity was recorded at a two-month follow-up. Results Forty-nine patients (26 i…

MucositisOropharyngeal mucositismedicine.medical_specialtyAdolescentLymphoblastic Leukemiamedicine.medical_treatmentchemistry.chemical_elementAntineoplastic AgentsZincGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineMucositisHumansChildGeneral DentistryStomatitisAcute leukemiaChemotherapyPain scoreLeukemiabusiness.industryResearchMean age030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in Dentistrymedicine.diseaseZincOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASFemaleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies

2021

Hypericumis a widely present plant, and extracts of its leaves, flowers, and aerial elements have been employed for many years as therapeutic cures for depression, skin wounds, and respiratory and inflammatory disorders. Hypericum also displays an ample variety of other biological actions, such as hypotensive, analgesic, anti-infective, anti-oxidant, and spasmolytic abilities. However, recent investigations highlighted that this species could be advantageous for the cure of other pathological situations, such as trigeminal neuralgia, as well as in the treatment of cancer. This review focuses on the in vitro and in vivo antitumor effects of St. John’s Wort (Hypericum perforatum), its derivat…

MyeloidAngiogenesisDrug Evaluation PreclinicalReviewPharmacologylcsh:Chemistrychemistry.chemical_compoundhyperforinDrug InteractionsMyeloid CellsLymphocyteslcsh:QH301-705.5SpectroscopybiologyapoptosisleukemiaHypericum perforatumGeneral MedicineComputer Science ApplicationsHypericinLeukemiamedicine.anatomical_structurephotodynamic therapyHematologic NeoplasmsHypericumHypericumSt. John’s wortlymphomaCatalysisInorganic ChemistryStructure-Activity Relationshipmultidrug resistanceIn vivoCell Line TumormedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationPlant Extractsbusiness.industryOrganic Chemistry<i>Hypericum</i>biology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicApoptosis; Hyperforin; Hypericin; Hypericum; Leukemia; Lymphoma; Mul-tidrug resistance; Photodynamic therapy; St. John’s wort; Animals; Antineoplastic Agents Phytogenic; Apoptosis; Cell Line Tumor; Cell Proliferation; Drug Evaluation Preclinical; Drug Interactions; Drug Resistance Neoplasm; Hematologic Neoplasms; Humans; Hypericum; Lymphocytes; Myeloid Cells; Plant Extracts; Structure-Activity RelationshipHyperforinchemistrylcsh:Biology (General)lcsh:QD1-999Drug Resistance NeoplasmhypericinbusinessInternational Journal of Molecular Sciences
researchProduct

Intravenous Busulfan for Autologous Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: a Survey of 952 Patients on Behalf of th…

2014

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67 +/- 2%, 53 +/- 2%, and 40 +/- 2%, respectively. The non-relapse mortality rate at 2 years was 7 +/- 1%. Five patients died from ve…

MyeloidMale[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyBone Marrow Transplantation/mortalitymedicine.medical_treatmentLeukemia Myeloid Acute/therapyHematopoietic stem cell transplantationAntineoplastic Agents Alkylating/administration & dosageLeukemia Myeloid Acute/mortalityGastroenterologyHSAC ONCAutologous stem-cell transplantationHematopoietic Stem Cell Transplantation/mortalityInfusions IntravenousBone Marrow TransplantationAcute leukemiaSurvival Rate/trendsTransplantation Autologous/mortalityLeukemiaData CollectionHematopoietic Stem Cell Transplantation[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedAlkylating3. Good healthEuropeSurvival RateLeukemia Myeloid AcuteLeukemiaFemaleIntravenousAutologousmedicine.drugAdultBusulfan/administration & dosageInfusionsmedicine.medical_specialtyAdolescentCyclophosphamideAntineoplastic AgentsAcuteTransplantation AutologousEurope/epidemiologyData Collection/methodsYoung AdultInternal medicinemedicineHumansAntineoplastic Agents AlkylatingBusulfanSurvival rateAgedRetrospective StudiesTransplantationbusiness.industrySettore MED/15medicine.diseaseTransplantationAdolescent; Adult; Aged; Antineoplastic Agents Alkylating; Bone Marrow Transplantation; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions Intravenous; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Autologous; Young Adult; Data CollectionImmunologybusinessBusulfan
researchProduct

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

2020

Abstract The interaction of menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and provides a potential opportunity for treatment of NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. In this study, transcriptional profiling after pharmacological inhibition of the menin-MLL complex revealed specific changes in gene expression, with downregulation of the MEIS1 transcription factor and its transcriptional target gene FLT3 being the most pronounced. Combining menin-MLL inhibition with specific small-molecule kinase inhibitors…

NPM1Transcription GeneticImmunologyApoptosisBiochemistryMiceRandom AllocationMice Inbred NODCell Line TumorProto-Oncogene Proteinshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsGene expressionmedicineAnimalsHumansMEN1PhosphorylationMyeloid Ecotropic Viral Integration Site 1 ProteinProtein Kinase InhibitorsneoplasmsbiologyGene Expression Regulation LeukemicKinaseNuclear ProteinsMyeloid leukemiaDrug SynergismHistone-Lysine N-MethyltransferaseCell BiologyHematologymedicine.diseaseCoculture TechniquesNeoplasm ProteinsLeukemia Myeloid AcuteLeukemiaKMT2Afms-Like Tyrosine Kinase 3biology.proteinCancer researchNucleophosminProtein Processing Post-TranslationalTyrosine kinaseMyeloid-Lymphoid Leukemia ProteinBlood
researchProduct